microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
HER2
breast cancer
estrogen receptor
microRNA
progesterone receptor
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
20 Aug 2020
20 Aug 2020
Historique:
received:
27
06
2020
revised:
04
08
2020
accepted:
19
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Estrogen (ER) and progesterone (PgR) receptors and HER2 are crucial in the assessment of breast cancer specimens due to their prognostic and predictive significance. Single hormone receptor-positive breast cancers are less common and their clinical course is less favorable than ER(+)/PgR(+) tumors. Their molecular features, especially microRNA (miRNA) profiles, have not been investigated to date. Tumor specimens from 36 chemonaive breast cancer patients with known ER and PgR status (18 ER(+)/PgR(-) and 18 ER(-)/PgR(+) cases) were enrolled to the study. The expression of 829 miRNAs was evaluated with nCounter Human v3 miRNA expression Assay (NanoString). miRNAs differentiating between ER/PgR/HER2 phenotypes were selected based on fold change (FC) calculated for the mean normalized counts of each probe in compared groups. The differences were estimated with Student's
Identifiants
pubmed: 32825530
pii: diagnostics10090617
doi: 10.3390/diagnostics10090617
pmc: PMC7555149
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2017/25/B/NZ5/00656
Références
BMC Bioinformatics. 2018 Dec 31;19(Suppl 19):514
pubmed: 30598108
Oncogene. 2009 Nov 5;28(44):3926-36
pubmed: 19684618
Microrna. 2013;2(2):137-47
pubmed: 25070783
J Cancer. 2011 Feb 24;2:116-22
pubmed: 21479130
Mol Cancer. 2006 Jun 19;5:24
pubmed: 16784538
Oncotarget. 2017 Apr 18;8(16):25963-25976
pubmed: 28404930
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817685
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
J Natl Cancer Inst. 2017 Oct 1;109(10):
pubmed: 28383653
J Transl Med. 2019 Oct 3;17(1):334
pubmed: 31581940
PLoS One. 2012;7(2):e31422
pubmed: 22384020
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Pharmacogenomics. 2019 May;20(7):493-502
pubmed: 31124410
Oncogene. 2015 Jul;34(28):3676-87
pubmed: 25241899
Trends Endocrinol Metab. 2012 May;23(5):223-33
pubmed: 22503553
Sci Rep. 2019 Feb 20;9(1):2394
pubmed: 30787377
Cancer Res. 2010 Jun 1;70(11):4778-84
pubmed: 20484043
Oncol Rep. 2014 Mar;31(3):1096-102
pubmed: 24402230
BMC Med. 2015 Oct 05;13:254
pubmed: 26437901
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cancer Treat Rev. 2018 Jun;67:78-87
pubmed: 29772460
J Clin Oncol. 2005 Oct 20;23(30):7721-35
pubmed: 16234531
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Oncoscience. 2015 Dec 02;2(11):924-9
pubmed: 26697527
Sci Rep. 2019 Mar 4;9(1):3352
pubmed: 30833639
Cancer Res. 2009 Nov 1;69(21):8332-40
pubmed: 19826037
Onco Targets Ther. 2016 Mar 21;9:1707-13
pubmed: 27051305
Tumour Biol. 2017 Mar;39(3):1010428317692204
pubmed: 28347244
World J Surg Oncol. 2012 Aug 27;10:174
pubmed: 22925189
Cancer Res. 2020 Mar 1;80(5):1064-1077
pubmed: 31862778
Breast Cancer Res. 2009;11(3):R27
pubmed: 19432961
Nucleic Acids Res. 2016 Jul 8;44(W1):W135-41
pubmed: 27105848
BMC Genomics. 2019 Jun 17;20(1):503
pubmed: 31208318
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
BMC Bioinformatics. 2015;16 Suppl 4:S7
pubmed: 25734576